| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04339816 2020-001456-18 Details | 2020-11-06 Interventional | 3 | 3 | Azithromycin Hydroxychloroqu… COVID-19 Respiratory Ins… Respiratory Fai… | Steering Committee decision in accordance with stopping rule 1: Emergence of new data - | |||
| NCT03292172 2017-001147-13 Details | 2020-11-06 Interventional | 1 | 36 | Atezolizumab Breast Neoplasm… Carcinoma, Ovar… Ovarian Neoplas… Triple Negative… Advanced Ovaria… Triple Negative… | Portfolio prioritization - | |||
| NCT02842580 Details | 2020-11-06 Interventional | 2 | 20 | Bevacizumab Capecitabine Irinotecan Leucovorin Levoleucovorin Oxaliplatin Colorectal Neop… | Inclusion rythm too slow. - | |||
| NCT00808210 Details | 2020-11-06 Interventional | 2 | 28 | Infliximab Methotrexate Methylprednisol… Ocrelizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | Based on analysis of results and consideration of available treatments, the overall benefit to
risk profile of ocrelizumab was not favorable in RA. At the time of study termination the scope of the statistical analyses was reduced and limited to evaluation of the safety profile. | |||
| NCT04094766 Details | 2020-11-05 Interventional | 1 | 0 | Immunomodulatin… Leukemia Leukemia, Lymph… Precursor Cell … Refractory B Ac… Relapse B Acute… | Production plan adjustment - | |||
| NCT02973295 Details | 2020-11-05 Interventional | 4 | 0 | Silymarin Fatty Liver Liver Diseases Non-alcoholic F… Non-Alcoholic F… | Sponsor withdrawn their agreement - | |||
| NCT02495454 2014-005697-10 Details | 2020-11-05 Interventional | 2 | 34 | Obinutuzumab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Non-H… CD20 Positive D… Elderly Unfit P… | Primary objective not obtained after interim analysis - | |||
| NCT02144142 Details | 2020-11-05 Interventional | 2 | 0 | Anti-Bacterial … Anti-Infective … Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | This sub-study was not done because main study results reached significance. - | |||
| NCT01960764 Details | 2020-11-05 Interventional | 1 | 0 | Anti-Bacterial … Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | This sub-study was not done because main study results reached significance. - | |||
| NCT01673984 2011-004213-16 Details | 2020-11-05 Interventional | 4 | 27 | Goserelin Triptorelin Pam… Prostatic Neopl… Prostate Cancer | The study was discontinued prematurely by the sponsor due to non-medical reasons - | |||
| NCT00986440 Details | 2020-11-05 Interventional | 2 | 84 | Efatutazone Colorectal Neop… Colorectal Canc… | Due to changes to the standard of care within the proposed market for CS-7017. Early termination was due to changes in the standard of care within the proposed market. The study was designed when patient monitoring and no treatment was an option that will not support a confirmatory Phase 3 study. No safety or efficacy concerns. | |||
| NCT02010567 Details | 2020-11-03 Interventional | 1/2 | 32 | Capecitabine Rectal Neoplasm… Rectal Cancer | The study was halted prematurely at the funding partner's request. Follow-up of participants was ended early, resulting in few or no observed events (progression or death) for all survival endpoints. | |||
| NCT00503581 Details | 2020-11-03 Interventional | 2 | 9 | Megestrol Megestrol Aceta… Carcinoma in Si… Endometrial Hyp… Hyperplasia Neoplasms High Grade Squa… Stage 0 Uterine… | - - | |||
| NCT00485589 Details | 2020-11-03 Interventional | 3 | 613 | Methotrexate Ocrelizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | Based on analysis of results and consideration of available treatments, the overall benefit to
risk profile of ocrelizumab was not favorable in RA. The study was terminated prematurely by the sponsors before all patients could reach the time point for primary analysis at Week 104. No patient received any further infusions of study medication. | |||
| NCT04610879 2018-003893-29 Details | 2020-11-02 Interventional | 4 | 5 | Carbamazepine Levetiracetam Epilepsy Epilepsy, Rolan… Rolandic Epilep… | Following the internal pilot, the study did not meet prespecified stop/go criteria for
continuation. - | |||
| NCT04374552 Details | 2020-11-02 Interventional | 2 | 0 | Azithromycin Hydroxychloroqu… COVID-19 SARS-CoV-2 Infe… | The investigators have decided not to go forward with this protocol - | |||
| NCT04347889 Details | 2020-11-02 Interventional | 2 | 0 | Hydroxychloroqu… COVID-19 Covid-19 | Evidence that HCQ ineffective, loss of HCW interest, - | |||
| NCT04340544 Details | 2020-11-02 Interventional | 2 | 17 | Hydroxychloroqu… COVID-19 | It appeared to be impossible for the study centres to recruit the targeted number of patients,
due to reduced incidence and reduced acceptance to IMP - | |||
| NCT02266433 Details | 2020-11-02 Interventional | 3 | 245 | Dexamethasone Ketorolac Tennis Elbow Tenosynovitis Trigger Finger … DeQuervains Ten… Inflammatory Di… Lateral Epicond… Trigger Finger | due to PI's change to private practice - | |||
| NCT01068873 Details | 2020-11-02 Interventional | 4 | 1 | Lopinavir Maraviroc Ritonavir HIV Infections | Poor enrollment - |